Skip to main content

Advertisement

SpringerLink
Log in

Security and efficiency of a closed-system, turbulent-flow circuit for hyperthermic intraperitoneal chemotherapy after cytoreductive ovarian surgery: perioperative outputs

  • Gynecologic Oncology
  • Published:
Archives of Gynecology and Obstetrics Aims and scope Submit manuscript

Abstract

Objective

To present physiologic intraoperative data and immediate postoperative outcomes of patients diagnosed with epithelial ovarian cancer submitted to cytoreductive surgery and hyperthermic peritoneal intraoperative chemotherapy (HIPEC) with a closed-circuit, turbulent-flow system.

Materials and methods

A closed-circuit system with CO2 turbulent flow was used for paclitaxel HIPEC during 60 min for patients diagnosed with stage II or higher and recurrent epithelial ovarian cancer. Perioperative hemodynamic and metabolic statuses were followed, as well as physiologic recovery during the first 12 postoperative hours. A non-parametric statistical analysis was performed.

Results

At the end of the hyperthermia phase, temperature was 37.7 ± 0.6 °C, heart rate 88 ± 19 bpm, cardiac index 2.8 ± 0.5 L min−1 m−2, stroke volume variation 14.6 ± 3.6 % and extravascular lung water 8.7 ± 1.9 mL kg−1. No hyperdynamic status was recorded. The length of stay in the ICU was 2½ days, and 12.7 ± 7 days in hospital. Average postoperative intubation time was 11.7 ± 17.4 h. At the ICU admission time, glucose, lactic acid and hemoglobin were the only values out of range, but close to normal. SOFA median was 3 at admission and 0 the following day.

Conclusion

A turbulent-flow, closed-circuit use for hyperthermic peritoneal intraoperative chemotherapy resulted in no hyperdynamic response or coagulopathy, had good tolerance and promoted early physiologic recovery.

This is a preview of subscription content, log in via an institution to check access.

Access this article

Log in via an institution

Price excludes VAT (USA)
Tax calculation will be finalised during checkout.

Instant access to the full article PDF.

Institutional subscriptions

Fig. 1
Fig. 2
Fig. 3

Similar content being viewed by others

References

  1. Helm CW (2012) Current status and future directions of cytoreductive surgery and hyperthermic intraperitoneal chemotherapy in the treatment of ovarian cancer. Surg Oncol Clin N Am 21:645–663

    Article  PubMed  Google Scholar 

  2. Chang E, Alexander HR, Libutti SK, Hurst R, Zhai S, Fiff WD, Bartlett DL (2001) Laparoscopic continuous hyperthermic peritoneal perfusion. J Am Coll Surg 193:225–229

    Article  CAS  PubMed  Google Scholar 

  3. Kusamura S, Younan R, Baratti D, Costanzo P, Favaro M, Gavazzi C, Deraco M (2006) Cytoreductive surgery followed by intraperitoneal hyperthermic perfusion: analysis of morbidity and mortality in 209 peritoneal surface malignancies treated with closed abdomen technique. Cancer 106:1144–1153

    Article  PubMed  Google Scholar 

  4. Chan DL, Morris DL, Rao A, Chua TC (2012) Intraperitoneal chemotherapy in ovarian cancer, a review of tolerance and efficacy. Cancer Manag Res 4:413–422

    PubMed Central  PubMed  Google Scholar 

  5. Gesson-Paute A, Ferron G, Thomas F, de Lara EC, Chatelut E, Querleu D (2008) Pharmacokinetics of oxaliplatin during open versus laparoscopically assisted heated intraoperative intraperitoneal chemotherapy (HIPEC): an experimental study. Ann Surg Oncol 15:339–344

    Article  PubMed  Google Scholar 

  6. Tsiftsis D, de Bree E, Romanos J, Petrou A, Sanidas E, Askoxylakis J, Zervos K, Michaloudis D (1999) Peritoneal expansion by artificially produced ascites during perfusion chemotherapy. Arch Surg 134:545–549

    Article  CAS  PubMed  Google Scholar 

  7. Kim JH, Lee JM, Ryu KS, Lee YS, Park YG, Hur SY, Lee KH, Lee SH, Kim SJ (2010) Consolidation hyperthermic intraperitoneal chemotherapy using paclitaxel in patients with epithelial ovarian cancer. J Surg Oncol 101:149–155

    CAS  PubMed  Google Scholar 

  8. Panici PB, Palaia I, Graziano M, Bellati F, Manci N, Angioli RI (2010) Intraperitoneal paclitaxel as consolidation treatment in ovarian cancer patients: a case control study. Oncology 78:20–25

    Article  Google Scholar 

  9. de Bree E, Rosing H, Filis D, Romanos J, Melisssourgaki M, Daskalakis M, Pilatou M, Sanidas E, Taflampas P, Kalbakis K, Beijnen JH, Tsiftsis DD (2008) Cytoreductive surgery and intraoperative hyperthermic intraperitoneal chemotherapy with paclitaxel: a clinical and pharmacokinetic study. Ann Surg Oncol 15:1183–1192

    Article  PubMed  Google Scholar 

  10. Hofer CK, Senn A, Weibel L, Zollinger A (2008) Assessment of stroke volume variation for prediction of fluid responsiveness using the modified FloTrac and PiCCOplus system. Crit Care 12:R82

    Article  PubMed Central  PubMed  Google Scholar 

  11. Corcoran T, Rhodes JE, Clarke S, Myles PS, Ho KM (2012) Perioperative fluid management strategies in major surgery: a stratified meta-analysis. Anesth Analg 114:640–651

    Article  PubMed  Google Scholar 

  12. Chia VM, O’Malley CD, Danese MD, Lindquist KJ, Gleeson ML, Kelsh MA, Griffiths RA (2013) Prevalence and Incidence of comorbidities in elderly women with ovarian cancer. Gynecol Oncol 129(2):346–352

    Article  PubMed  Google Scholar 

  13. Raspe C, Piso P, Wiesenack C, Bucher M (2012) Anesthetic management in patients undergoing hyperthermic chemotherapy. Curr Opin Anaesthesiol 25:348–355

    Article  CAS  PubMed  Google Scholar 

  14. Benoit L, Cheynel N, Ortega-Deballon P, Di Giacomo G, Chauffert B, Rat P (2008) Closed hyperthermic intraperitoneal chemotherapy with open abdomen: a novel technique to reduce exposure of the surgical team to chemotherapy drugs. Ann Surg Oncol 15:542–546

    Article  PubMed Central  PubMed  Google Scholar 

  15. Esquivel J, Sticca R, Sugarbaker P, Society of Surgical Oncology et al (2007) Cytoreductive surgery and hyperthermic intraperitoneal chemotherapy in the management of peritoneal surface malignancies of colonic origin: a consensus statement. Ann Surg Oncol 14:128–133

    CAS  PubMed  Google Scholar 

  16. Cafiero T, Di Iorio C, Di Minno RM, Sivolella G, Confuorto G (2006) Non-invasive cardiac monitoring by aortic blood flow determination in patients undergoing hyperthermic intraperitoneal intraoperative chemotherapy. Minerva Anestesiol 72:207–215

    CAS  PubMed  Google Scholar 

  17. Bickel A, Arzomanov T, Ivry S, Zveibl F, Eitan A (2004) Reversal of adverse hemodynamic effects of pneumoperitoneum by pressure equilibration. Arch Surg 139:1320–1325

    Article  PubMed  Google Scholar 

  18. Esquivel J, Angulo F, Bland RK, Stephens AD, Sugarbaker PH (2000) Hemodynamic and cardiac function parameters during heated intraoperative intraperitoneal chemotherapy using the open ‘‘coliseum technique’’. Ann Surg Oncol 7:296–300

    Article  CAS  PubMed  Google Scholar 

  19. Kanakoudis F, Petrou A, Michaloudis D, Chortaria G, Konstantinidou A (1996) Anaesthesia for intra-peritoneal perfusion of hyperthermic chemotherapy. Haemodynamic changes, oxygen consumption and delivery. Anaesthesia 51:1033–1036

    Article  CAS  PubMed  Google Scholar 

  20. Sakka SG, Ruhl CC, Pfeiffer UJ, Beale R, McLuckie A, Reinhart K, Meier-Hellmann A (2000) Assessment of cardiac preload and extravascular lung water by single transpulmonary thermodilution. Intensive Care Med 26:180–187

    Article  CAS  PubMed  Google Scholar 

  21. Vorgias G, Iavazzo C, Mavromatis J, Leontara J, Katsoulis M, Kalinoglou N, Akrivos T (2007) Determination of the necessary total protein substitution requirements in patients with advanced stage ovarian cancer and ascites, undergoing debulking surgery. Correlation with plasma proteins. Ann Surg Oncol 14:1919–1923

    Article  PubMed  Google Scholar 

  22. Desgranges FP, Steghens A, Mithieux O, Rosay H (2010) Potential risks of thoracic epidural analgesia in hyperthermic intraperitoneal chemotherapy. J Surg Oncol 101:442

    PubMed  Google Scholar 

  23. Desgranges FP, Steghens A, Rosay H, Méeus P, Stoian A, Daunizeau AL, Pouderoux-Martin S, Piriou V (2012) Epidural analgesia for surgical treatment of peritoneal carcinomatosis: a risky technique? Ann Fr Anesth Reanim 31:53–59

    Article  PubMed  Google Scholar 

  24. Schmidt C, Creutzenberg M, Piso P, Hobbhahn J, Bucher M (2008) Peri-operative anaesthetic management of cytoreductive surgery with hyperthermic intraperitoneal chemotherapy. Anaesthesia 63:389–395

    Article  CAS  PubMed  Google Scholar 

  25. De Somer F, Ceelen W, Delanghe J, De Smet D, Vanackere M, Pattyn P, Mortier E (2008) Severe hyponatremia, hyperglycemia, and hyperlactatemia are associated with intraoperative hyperthermic intraperitoneal chemoperfusion with oxaliplatin. Perit Dial Int 28:61–66

    PubMed  Google Scholar 

  26. Raft J, Parisot M, Marchal F, Tala S, Desandes E, Lalot JM, Guillemin F, Longrois D, Meistelman C (2010) Impact of the hyperthermic intraperitoneal chemotherapy on the fluid-electrolytes changes and on the acid-base balance. Ann Fr Anesth Reanim 29:676–681

    Article  CAS  PubMed  Google Scholar 

  27. Argenta PA, Sueblinvong T, Geller MA, Jonson AL, Downs LS Jr, Carson LF, Ivy JJ, Judson PL (2013) Hyperthermic intraperitoneal chemotherapy with carboplatin for optimally-cytoreduced, recurrent, platinum-sensitive ovarian carcinoma: a pilot study. Gynecol Oncol 129:81–85

    Article  CAS  PubMed  Google Scholar 

  28. Frenel JS, Leux C, Pouplin L, Ferron G, Berton Rigaud D, Bourbouloux E, Dravet F, Jaffre I, Classe JM (2011) Oxaliplatin-based hyperthermic intraperitoneal chemotherapy in primary or recurrent epithelial ovarian cancer: a pilot study of 31 patients. J Surg Oncol 103:10–16

    Article  PubMed  Google Scholar 

  29. Ansaloni L, Agnoletti V, Amadori A, Catena F, Cavaliere D, Coccolini F, De Iaco P, Di Battista M, Framarini M, Gazzotti F, Ghermandi C, Kopf B, Saponara M, Tauceri F, Vallicelli C, Verdecchia GM, Pinna AD (2012) Evaluation of extensive cytoreductive surgery and hyperthermic intraperitoneal chemotherapy (HIPEC) in patients with advanced epithelial ovarian cancer. Int J Gynecol Cancer 22(5):778–785

    Article  PubMed  Google Scholar 

  30. Tentes AA, Kakolyris S, Kyziridis D, Karamveri C (2012) Cytoreductive surgery combined with hyperthermic intraperitoneal chemotherapy in the treatment of advanced epithelial ovarian cancer. J Oncol 2012:358341

    Article  PubMed Central  PubMed  Google Scholar 

  31. Konigsrainer I, Beckert S, Becker S, Zieker D, Fehm T, Grischke EM, Lauk O, Glatzle J, Brücher B, Wallwiener D, Königsrainer A (2011) Cytoreductive surgery and HIPEC in peritoneal recurrent ovarian cancer: experience and lessons learned. Langenbecks Ach Surg 396:1077–1081

    Article  Google Scholar 

  32. Fagotti A, Costantini B, Vizzielli G, Perelli F, Ercoli A, Gallotta V, Scambia G, Fanfani F (2011) HIPEC in recurrent ovarian cancer patients: morbidity-related treatment and long-term analysis of clinical outcome. Gynecol Oncol 122(2):221–225

    Article  PubMed  Google Scholar 

  33. Cascales Campos PA, Gil Martinez J, Galindo Fernandez PJ et al (2011) Perioperative fast track program in intraoperative hyperthermic intraperitoneal chemotherapy (HIPEC) after cytoreductive surgery in advanced ovarian cancer. Eur J Surg Oncol 37:543–548

    Article  CAS  PubMed  Google Scholar 

  34. Deraco M, Kusamura S, Virzì S, Puccio F, Macrì A, Famulari C, Solazzo M, Bonomi S, Iusco DR, Baratti D (2011) Cytoreductive surgery and hyperthermic intraperitoneal chemotherapy as upfront therapy for advanced epithelial ovarian cancer: multi-institutional phase-II trial. Gynecol Oncol 122:215–220

    Article  PubMed  Google Scholar 

  35. Roviello F, Pinto E, Corso G, Pedrazzani C, Caruso S, Filippeschi M, Petrioli R, Marsili S, Mazzei MA, Marrelli D (2010) Safety and potential benefit of hyperthermic intraperitoneal chemotherapy (HIPEC) in peritoneal carcinomatosis from primary or recurrent ovarian cancer. J Surg Oncol 102:663–670

    Article  PubMed  Google Scholar 

  36. Pomel C, Ferron G, Lorimier G et al (2010) Hyperthermic intra-peritoneal chemotherapy using oxaliplatin as consolidation therapy for advanced epithelial ovarian carcinoma. Results of a phase II prospective multicentre trial. CHIPOVAC study. Eur J Surg Oncol 36:589–593

    Article  CAS  PubMed  Google Scholar 

  37. Ceelen WP, Van Nieuwenhove Y, Van Belle S, Denys H, Pattyn P (2009) Cytoreduction and hyperthermic intraperitoneal chemoperfusion in women with heavily pretreated recurrent ovarian cancer. Ann Surg Oncol 19:2352–2359

    Article  PubMed  Google Scholar 

  38. Lim MC, Kang S, Choi J, Song YJ, Park S, Seo SS, Park SY (2009) Hyperthermic intraperitoneal chemotherapy after extensive cytoreductive surgery in patients with primary advanced epithelial ovarian cancer: interim analysis of a phase II study. Ann Surg Oncol 16:993–1000

    Article  PubMed  Google Scholar 

  39. Bereder J, Glehen O, Habre J (2009) Cytoreductive surgery combined with perioperative intraperitoneal chemotherapy for the management of peritoneal carcinomatosis from ovarian cancer: a multiinstitutional study of 246 patients. J Clin Oncol 27(Suppl 15):Abstract 5542

  40. Pavlov MJ, Kovacevic PA, Ceranic MS, Stamenkovic AB, Ivanovic AM, Kecmanovic DM (2009) Cytoreductive surgery and modified heated intraoperative intraperitoneal chemotherapy (HIPEC) for advanced and recurrent ovarian cancer—12-year single center experience. Eur J Surg Oncol 35:1186–1191

    Article  CAS  PubMed  Google Scholar 

  41. Guardiola E, Delroeux D, Heyd B, Combe M, Lorgis V, Demarchi M, Stein U, Royer B, Chauffert B, Pivot X (2009) Intra-operative intra-peritoneal chemotherapy with cisplatin in patients with peritoneal carcinomatosis of ovarian cancer. World J Surg Oncol 7:14

    Article  PubMed Central  PubMed  Google Scholar 

  42. Di Giorgio A, Naticchioni E, Biacchi D, Sibio S, Accarpio F, Rocco M, Tarquini S, Di Seri M, Ciardi A, Montruccoli D, Sammartino P (2008) Cytoreductive surgery (peritonectomy procedures) combined with hyperthermic intraperitoneal chemotherapy (HIPEC) in the treatment of diffuse peritoneal carcinomatosis from ovarian cancer. Cancer 113:315–325

    Article  PubMed  Google Scholar 

  43. Bae JH, Lee JM, Ryu KS, Lee YS, Park YG, Hur SY, Ahn WS, Namkoong SE (2007) Treatment of ovarian cancer with paclitaxel- or carboplatin-based intraperitoneal hyperthermic chemotherapy during secondary surgery. Gynecol Oncol 106:193–200

    Article  CAS  PubMed  Google Scholar 

  44. Cotte E, Glehen O, Mohamed F, Lamy F, Falandry C, Golfier F, Gilly FN (2007) Cytoreductive surgery and intraperitoneal chemo-hyperthermia for chemo-resistant and recurrent advanced epithelial ovarian cancer: prospective study of 81 patients. World J Surg 31:1813–1820

    Article  PubMed  Google Scholar 

  45. Helm CW, Randall-Whitis L, Martin RS 3rd, Metzinger DS, Gordinier ME, Parker LP, Edwards RP (2007) Hyperthermic intraperitoneal chemotherapy in conjunction with surgery for the treatment of recurrent ovarian carcinoma. Gynecol Oncol 105:90–96

    Article  CAS  PubMed  Google Scholar 

  46. Rufian S, Muñoz-Casares FC, Briceno J, Diaz CJ, Rubio MJ, Ortega R, Ciria R, Morillo M, Aranda E, Muntané J, Pera C (2006) Radical surgery-peritonectomy and intraoperative intraperitoneal chemotherapy for the treatment of peritoneal carcinomatosis in recurrent or primary ovarian cancer. J Surg Oncol 94:316–324

    Article  PubMed  Google Scholar 

  47. Raspagliesi F, Kusamura S, Campos Torres JC, de Souza GA, Ditto A, Zanaboni F, Younan R, Baratti D, Mariani L, latterza B, Deraco M (2006) Cytoreduction combined with intraperitoneal hyperthermic perfusion chemotherapy in advanced/recurrent ovarian cancer patients: the experience of National Cancer Institute of Milan. Eur J Surg Oncol 32:671–675

    Article  CAS  PubMed  Google Scholar 

  48. Look M, Chang D, Sugarbaker PH (2004) Long-term results of cytoreductive surgery for advanced and recurrent epithelial ovarian cancers and papillary serous carcinoma of the peritoneum. Int J Gynecol Cancer 14:35–41

    Article  CAS  PubMed  Google Scholar 

  49. Ryu KS, Kim JH, Ko HS, Kim JW, Ahn WS, Park YG, Kim SJ, Lee JM (2004) Effects of intraperitoneal hyperthermic chemotherapy in ovarian cancer. Gynecol Oncol 94:325–332

    Article  CAS  PubMed  Google Scholar 

  50. Piso M, Dahlke MH, Loss M, Schlitt HJ (2004) Cytoreductive surgery and hyperthermic intraperitoneal chemotherapy in peritoneal carcinomatosis from ovarian cancer. World J Surg Oncol 2:21

    Article  PubMed Central  PubMed  Google Scholar 

  51. Zanon C, Clara R, Chiappino I, Bortolini M, Cornaglia S, Simone P, Bruno F, De Riu L, Airoldi M, Pedani F (2004) Cytoreductive surgery and intraperitoneal chemohyperthermia for recurrent peritoneal carcinomatosis from ovarian cancer. World J Surg 28:1040–1045

    Article  PubMed  Google Scholar 

  52. Chatzigeorgiou K, Economou S, Chrysafis G, Dimasis A, Zafiriou G, Setzis K, Lyratzopoulos N, Minopoulos G, Manolas K, Chatzigeorgiou N (2003) Treatment of recurrent epithelial ovarian cancer with secondary cytoreduction and continuous intraoperative intraperitoneal hyperthermic chemoperfusion (CIIPHCP). Zentralbl Gynakol 125:424–429

    Article  CAS  PubMed  Google Scholar 

  53. de Bree E, Romanos J, Michalakis J, Relakis K, Georgoulias V, Melissas J, Tsiftsis DD (2003) Intraoperative hyperthermic intraperitoneal chemotherapy with docetaxel as second-line treatment for peritoneal carcinomatosis of gynaecological origin. Anticancer Res 23:3019–3027

    PubMed  Google Scholar 

Download references

Conflict of interest

Dr Villarejo has a Government grant for a Clinical Trial to compare plain surgery with surgery plus intraoperative hyperthermic paclitaxel chemotherapy. The device we used for this pilot series is the Combat PRS™ (Peritoneum Recirculation System, Galmaz Biotech, Madrid, Spain), borrowed at no cost by the owner.

Author information

Authors and Affiliations

  1. Department of Anesthesiology, Hospital General Universitario de Ciudad Real, c/ Obispo Rafael Torija s/n, 13005, Ciudad Real, Spain

    Javier Pascual-Ramírez & Francisco González Ruiz de la Herrán

  2. Department of Surgery, Hospital General Universitario de Ciudad Real, Ciudad Real, Spain

    Susana Sánchez García, Pedro Villarejo Campos, David Padilla Valverde & Jesús Martín Fernández

  3. Department of Gynecology, Hospital General Universitario de Ciudad Real, Ciudad Real, Spain

    Carlos López de la Manzanara Cano & Javier Haya Palazuelo

Authors
  1. Javier Pascual-Ramírez
    View author publications

    You can also search for this author in PubMed Google Scholar

  2. Susana Sánchez García
    View author publications

    You can also search for this author in PubMed Google Scholar

  3. Francisco González Ruiz de la Herrán
    View author publications

    You can also search for this author in PubMed Google Scholar

  4. Pedro Villarejo Campos
    View author publications

    You can also search for this author in PubMed Google Scholar

  5. Carlos López de la Manzanara Cano
    View author publications

    You can also search for this author in PubMed Google Scholar

  6. Javier Haya Palazuelo
    View author publications

    You can also search for this author in PubMed Google Scholar

  7. David Padilla Valverde
    View author publications

    You can also search for this author in PubMed Google Scholar

  8. Jesús Martín Fernández
    View author publications

    You can also search for this author in PubMed Google Scholar

Corresponding author

Correspondence to Javier Pascual-Ramírez.

Rights and permissions

Reprints and permissions

About this article

Cite this article

Pascual-Ramírez, J., Sánchez García, S., González Ruiz de la Herrán, F. et al. Security and efficiency of a closed-system, turbulent-flow circuit for hyperthermic intraperitoneal chemotherapy after cytoreductive ovarian surgery: perioperative outputs. Arch Gynecol Obstet 290, 121–129 (2014). https://doi.org/10.1007/s00404-014-3153-4

Download citation

  • Received:

  • Accepted:

  • Published:

  • Issue Date:

  • DOI: https://doi.org/10.1007/s00404-014-3153-4

Keywords

Search

Navigation